Mabel M Ryder MD
Diabetes, Lipid Metabolism
Assistant Professor, Internal Medicine, Mayo Med Sch
Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Ryder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2002 - 2004
Baylor College of MedicineInternship, Internal Medicine, 2001 - 2002
University of Texas Medical Branch School of MedicineClass of 2001
Certifications & Licensure
MN State Medical License 2013 - 2027
NY State Medical License 2006 - 2014
OH State Medical License 2002 - 2008
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
- CMS Meaningful Use Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017
- CMS Meaningful Use Stage 2 Certification Mayo Clinic Incorporate Lab Results, Mayo Clinic, 2014-2017
Clinical Trials
- Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer Start of enrollment: 2021 Jun 24
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Outcomes of Peptide Receptor Radionuclide Therapy withLu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma.Gokce Belge Bilgin, Brian J Burkett, Cem Bilgin, Jolanta M Durski, Ann T Packard
Journal of Nuclear Medicine. 2026-01-02 - Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2025-06-17 - 8 citationsRedifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement.Sophie Leboulleux, Laura Boucai, Naifa Busaidy, Cosimo Durante, James A Fagin
The Lancet. Diabetes & Endocrinology. 2025-06-01
Press Mentions
Study Identifies Patients Who Would Benefit from Redifferentiation Therapy for Thyroid CancerDecember 6th, 2025- Minnesota Oncology Specialist Taps Mayo Clinic Resource, Transforms Patient JourneyMarch 24th, 2025
- Living with Thyroid Cancer?January 5th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
